Pharsight

Tivicay generic

Tivicay is an antiviral medication owned by Viiv Healthcare. The drug, which contains the active ingredient dolutegravir sodium, was first authorized for market use on 12 August, 2013. Tivicay is available in tablet form for oral administration and has a total of 4 patents, none of which have expired yet.

When will Tivicay generic be available?

The last patent of Tivicay is set to expire on 08 June, 2030. It is then that the generics of Tivicay can potentially be released. The last patent extension, identified as US9242986*PED, pertains to a method for synthesizing carbamoylpyridone HIV integrase inhibitors and intermediates.

Tivicay uses

Tivicay is used to treat HIV infection. Its active ingredient, dolutegravir sodium, inhibits the HIV integrase enzyme, preventing replication of the virus and thus controlling the infection.

Tivicay patent expiration

Tivicay holds four patents, with the final one expiring on 8 June, 2030. Therefore, the potential availability of the Tivicay generic could be after this date. The two key patents, US8129385 and US9242986, are related to the substance of the drug and its synthesis, respectively. Below are the details of the patents:

EPO Oppostions filed on Tivicay

Tivicay dosage

Want to ask something?